Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for ...

In ONTARGET patients, glomerular filtration rate (GFR) decline averaged 0.9 ml/min per year, which is within the physiologic range of GFR loss (0.6–1.1 ml/min per year) observed in healthy ...

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 ...

Research and Development: The R&D expense decreased by $2.1 million, from $18.6 million for the year ended December 31, 2023 compared to $16.5 million in 2024, primarily due to the conclusion of the ...

Jaguar Health’s (JAGX) Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget ...

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 ...

with additional POC IIT results expected throughout 2025 FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the ...